ArticleCancer cell international2025
Construction of anti-tumor immune gene signature for HNSCC and identification of 4'-Hydroxywogonin as a potential immunotherapy combination drug.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHead and neck squamous cell carcinoma (HNSCC) is an aggressive and heterogeneous malignancy, presenting challenges in accurately forecasting prognosis and immunotherapy response. This study endeavors to develop a robust gene signature to augment the prognostic prediction of HNSCC, and simultaneously uncover potential immunotherapy combination drug.
methodsTranscriptome data from clinical HNSCC patients were analyzed using LASSO regression algorithm to construct a gene signature, followed by survival curve and ROC curve analyses, immune correlation analysis, and nomogram building. Furthermore, a comprehensive virtual screening of approximately 30,000 molecules was carried out based on the key target of signature. Finally, the potential immunotherapy combination drug was identified by molecular docking, CCK-8 assay, RT-qPCR assay, and molecular dynamics simulation.
resultsAn anti-tumor immune gene signature (ATIGS) comprising 14 genes was established, which had promising potential in predicting the prognosis of HNSCC patients and could serve as an independent prognostic factor. Notably, ATIGS demonstrated a significant correlation with the infiltration level of several immune cells in the tumor immune microenvironment. It also had a good performance in predicting the response to immunotherapy. Further, protein-protein interaction (PPI) network analysis identified ZAP70 as a key target of ATIGS. Virtual screening of ~ 30,000 compounds found Puerol A, 4'-Hydroxywogonin, and Cirsimaritin as candidates, with 4'-Hydroxywogonin showing the strongest inhibition of CAL-27 and SCC7 cells. It also upregulated the expression levels of immune-related genes ZAP70 and LAT in CAL-27 cells, hinting at anti-tumor effect via immune pathway regulation. Molecular dynamics simulation showed stable binding of 4'-Hydroxywogonin to ZAP70 through hydrogen bonds and hydrophobic interactions, involving residues ALA417, GLU295, and LYS369.
conclusionsThis study successfully constructed a robust gene signature ATIGS, as well as identified a potential immunotherapy combination drug 4'-Hydroxywogonin. The ATIGS could effectively predict the prognosis and immunotherapy response of HNSCC patients, which may contribute towards enriching the immunotherapy-responsive population and enhancing the clinical efficacy of immunotherapy. Meanwhile, 4'-Hydroxywogonin may provide a promising clinical treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.